Sharon Saydah

Nov 13, 2024 | science.org | Sharon Saydah |Michael J Peluso |Julio César Silva |Júlio Silva |Alexandra Schafer

AbstractThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) pandemic has caused more than 7 million deaths globally. Despite the presence of infection- and vaccine-induced immunity, SARS-CoV-2 infections remain a major global health concern because of the emergence of SARS-CoV-2 variants that can cause severe acute coronavirus disease 2019 (COVID-19) or enhance Long Covid disease phenotypes.

Nov 13, 2024 | science.org | Sharon Saydah |Michael J Peluso |Julio César Silva |Júlio Silva |Rebecca Hamlin

Editor’s summarySex differences have been reported for both acute coronavirus disease 2019 (COVID-19) and Long Covid (LC), with males typically having more severe acute disease and females being more likely to develop LC. Here, Hamlin et al. performed multiomics on peripheral blood samples from a prospective cohort of individuals to understand why. The authors identified immune pathways during acute infection that were associated with later development of LC.

Nov 13, 2024 | science.org | Sharon Saydah |Michael J Peluso |Julio César Silva |Júlio Silva |Andrea Cox

AbstractLong Covid is defined by a wide range of symptoms that persist after the acute phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Commonly reported symptoms include fatigue, weakness, postexertional malaise, and cognitive dysfunction, with many other symptoms reported.

Aug 28, 2024 | nature.com | Michael J Peluso |Michelle Davidson |Sarah Goldberg |Jessica Chen |Badri Viswanathan |Kevin C. Donohue | +8 more

AbstractTo understand the roles of acute-phase viral dynamics and host immune responses in post-acute sequelae of SARS-CoV-2 infection (PASC), we enrolled 136 participants within 5 days of their first positive SARS-CoV-2 real-time PCR test. Participants self-collected up to 21 nasal specimens within the first 28 days post-symptom onset; interviewer-administered questionnaires and blood samples were collected at enrollment, days 9, 14, 21, 28, and month 4 and 8 post-symptom onset.